



Incyte to Host Webcast and Conference Call on October 26, 10:30 p.m. Eastern Time / 7:30 p.m. Pacific Time

October 23, 2008

WILMINGTON, Del.--(BUSINESS WIRE)--

Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled a webcast and conference call for 10:30 p.m. Eastern Time / 7:30 p.m. Pacific Time on Sunday, October 26, 2008 to discuss clinical results from a Phase IIa trial of INCB18424, its oral JAK 1&2 inhibitor, in patients with rheumatoid arthritis. Results from the Phase IIa trial will be presented at the 2008 American College of Rheumatology (ACR) Annual Scientific Meeting that is being held in San Francisco (details below):

Presentation Title: A Randomized Placebo-Controlled Study of
INCB18424, a Selective Janus Kinase 1&2
(JAK1&2) Inhibitor in Rheumatoid Arthritis (RA)
Presenting Author: Larry Moreland
Session Name: RA Treatment: Small Molecules and Gene Therapy
Session Time: Sunday October 26, 2008 4:30 p.m. - 6:00 p.m.
Pacific Time
Presentation Time: 4:30 p.m. - 4:45 p.m. Pacific Time
Location: Hall B
Presentation Number: 714

The schedules for the press release, webcast and conference call are as follows:

ACR Press Release: October 26, 2008 at 4:45 p.m. Pacific
Time / 7:45 p.m. Eastern Time

ACR Webcast & Conference Call: October 26, 2008 at 7:30 p.m. Pacific
Time / 10:30 p.m. Eastern Time

The live webcast with slides from the presentation can be accessed on Incyte's website: <http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-Calendar>

Analysts and investors are also invited to participate in the conference call by calling the following toll free numbers:

Domestic Dial In Number: 877-407-8037
International Dial In Number: 201-689-8037
Conference ID #: 300810

Please connect to Incyte's website prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.

If you are unable to participate, a replay of the webcast will be available on Incyte's website for 30 days and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs. Incyte's pipeline includes multiple compounds in Phase I and Phase II development for oncology, inflammation and diabetes. For additional information on Incyte, visit the Company's web site at www.incyte.com.

Source: Incyte Corporation